A new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast cancer

Basit Öğe Kaydı
dc.authoridZarepour, Atefeh/0000-0002-0347-5840
dc.authoridZarrabi, Ali/0000-0003-0391-1769
dc.authoridSaharkhiz, Shaghayegh/0009-0001-3377-2934
dc.authorwosidZarepour, Atefeh/AAH-9225-2020
dc.authorwosidZarrabi, Ali/U-2602-2019
dc.contributor.authorSaharkhiz, Shaghayegh
dc.contributor.authorZarepour, Atefeh
dc.contributor.authorZarrabi, Ali
dc.date.accessioned2024-05-19T14:39:47Z
dc.date.available2024-05-19T14:39:47Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractAs one of the newest generations of nanoplatforms, smart nanotheranostics have attracted signifivant attentions for medical applications, especially in oncology and cancer treatment. Indeed, their capability to provide treatment and diagnosis simultaneously leads to reduce time and side effects along with improving the performance. This study aims to introduce a novel smart nano-platform composed of doxorubicin-loaded pH-responsive stealth niosomes containing CdSe/ZnS Quantum dots as an imaging agent. Drug loaded nano-platform was fabricated via thin-film hydration method and then evaluated using different physicochemical tests. The entrapment efficiency and release profile of doxorubicin were assessed at three different pH (4, 6.5, and 7.4). Biological features and imaging ability of the nanoparticles were also evaluated by MTT assay, apoptosis assay, and fluorescence microscopy. Results showed that the fabricated nanoparticles were round-shaped, with a mean size of about 100 +/- 10 nm, -2 mV surface charge, and about 87% entrapment efficiency. The drug release profile presented a pH-responsive behavior (80, 60, and 40% drug release in pH 4, 6.5, and 7.4, respectively). The bioactivity assessments showed nearly 55% cytotoxicity effects via inducing cell apoptosis. Besides, the uptake of samples by the cells was confirmed through fluorescence imaging. Based on the results, this new nanoformulation could be considered as a candidate for future cancer theranostic applications.en_US
dc.identifier.doi10.1016/j.ijpharm.2023.122845
dc.identifier.issn0378-5173
dc.identifier.issn1873-3476
dc.identifier.pmid36958608en_US
dc.identifier.scopus2-s2.0-85151041609en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org10.1016/j.ijpharm.2023.122845
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4848
dc.identifier.volume637en_US
dc.identifier.wosWOS:000995105700001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofInternational Journal of Pharmaceuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectCancer Theranosticen_US
dc.subjectNiosomeen_US
dc.subjectPh -Sensitiveen_US
dc.subjectCdseen_US
dc.subjectZnsen_US
dc.subjectApoptosisen_US
dc.titleA new theranostic pH-responsive niosome formulation for doxorubicin delivery and bio-imaging against breast canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu